Currently, there are 1.28B common shares owned by the public and among those 1.28B shares have been available to trade.
The company’s stock has a 5-day price change of 0.54% and -5.82% over the past three months. MDT shares are trading 10.07% year to date (YTD), with the 12-month market performance up to 6.92% higher. It has a 12-month low price of $75.96 and touched a high of $96.25 over the same period. MDT has an average intraday trading volume of 7.94 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.22%, 4.24%, and 0.76% respectively.
Institutional ownership of Medtronic Plc (NYSE: MDT) shares accounts for 85.88% of the company’s 1.28B shares outstanding.
It has a market capitalization of $112.76B and a beta (3y monthly) value of 0.81. The stock’s trailing 12-month PE ratio is 24.31, while the earnings-per-share (ttm) stands at $3.62. The company has a PEG of 4.39 and a Quick Ratio of 1.42 with the debt-to-equity ratio at 0.59. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.95% over the week and 1.42% over the month.
Earnings per share for the fiscal year are expected to increase by 1.05%, and 7.86% over the next financial year. EPS should grow at an annualized rate of 5.54% over the next five years, compared to 0.37% over the past 5-year period.
Looking at the support for the MDT, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on June 16, 2025, with the firm’s price target at $110. Citigroup coverage for the Medtronic Plc (MDT) stock in a research note released on March 04, 2025 offered a Buy rating with a price target of $107. RBC Capital Mkts was of a view on October 10, 2024 that the stock is Outperform, while Oppenheimer gave the stock Perform rating on August 21, 2024, issuing a price target of $92- $94. UBS on their part issued Neutral rating on August 15, 2024.
